ABCC2/Abcc2 transport property in different species and its modulation by heterogeneous factors

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 6, 2008, Pages 394-405

  Ito, Kousei ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

ABC transporters; ABCC; ADME; Cholestasis; Glucuronide conjugates; Glutathione conjugates; Hepatobiliary transport; Isolated membranes; Organic anions

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C2; ANTICONVULSIVE AGENT; BENZBROMARONE; BOSENTAN; CHELERYTHRINE; DICLOFENAC; FEXOFENADINE; FUROSEMIDE; GLIBENCLAMIDE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; INDOMETACIN; LANSOPRAZOLE; MYCOPHENOLIC ACID; OMEPRAZOLE; ORGANIC ANION TRANSPORTER; PANTOPRAZOLE; PENICILLIN G; PHENYTOIN; PROBENECID; SAQUINAVIR; SULFINPYRAZONE; TAUROCHENODEOXYCHOLIC ACID; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; TEMOCAPRILAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

BILE; BILIARY EXCRETION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESEARCH; DRUG TISSUE LEVEL; DRUG TRANSPORT; ENZYME SPECIFICITY; EPILEPSY; EXPERIMENTAL MODEL; HEPATOBILIARY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRAHEPATIC BILE DUCT; LIVER CELL; MODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REVIEW; SPECIES DIFFERENCE; TISSUE DISTRIBUTION; TOXICOKINETICS;

EID: 67649342619     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.394     Document Type: Review

References (69)

1. Borst, P., Zelcer, N. and van de Wetering, K.: MRP2 and 3 in health and disease. Cancer Lett., 234: 51-61 (2006).
2. Nies, A. T. and Keppler, D.: The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch., 453: 643-659 (2007).
3. Leslie, E. M., Deeley, R. G. and Cole, S. P.: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204: 216-237 (2005).
4. Elferink, R. P., Ottenhoff, R., Liefting, W., de Haan, J. and Jansen, P. L.: Hepatobiliary transport of glutathione and glutathione conjugate in rats with hereditary hyperbilirubinemia. J. Clin. Invest. 84: 476-483 (1989).
5. Takikawa, H., Sano, N., Narita, T., Uchida, Y., Yamanaka, M., Horie, T., Mikami, T. and Tagaya, O.: Biliary excretion of bile acid conjugates in a hyperbilirubinemic mutant Sprague-Dawley rat. Hepatology, 14: 352-360 (1991).
6. Keppler, D. and Konig, J.: Hepatic canalicular membrane 5: Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/ cMOAT) gene in liver. Faseb. J., 11: 509-516 (1997).
7. Konig, J., Nies, A. T., Cui, Y., Leier, I. and Keppler, D.: Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta., 1461: 377-394 (1999).
8. Jansen, P. L., Peters, W. H. and Lamers, W. H.: Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology, 5: 573-579 (1985).
9. Kuipers, F., Radominska, A., Zimniak, P., Little, J. M., Havinga, R., Vonk, R. J. and Lester, R.: Defective biliary secretion of bile acid 3-O-glucuronides in rats with hereditary conjugated hyper-bilirubinemia. J. Lipid. Res., 30: 1835-1845 (1989).
10. Mikami, T., Nozaki, T., Tagaya, O., Hosokawa, S., Nakura, T., Hori, H. and Kondou, S.: The characters of a new mutant rats with hyperbilirubinuria syndrome. Cong. Anom., 26: 250-251 (1986).
11. Buchler, M., Konig, J., Brom, M., Kartenbeck, J., Spring, H., Horie, T. and Keppler, D.: cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyper-bilirubinemic mutant rats. J. Biol. Chem., 271: 15091-15098 (1996).
12. Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T. and Sugiyama, Y.: Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol., 272: G16-22 (1997).
13. Paulusma, C. C., Bosma, P. J., Zaman, G. J., Bakker, C. T., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P. and Oude Elferink, R. P.: Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science, 271: 1126-1128 (1996).
14. Chu, X. Y., Strauss, J. R., Mariano, M. A., Li, J., Newton, D. J., Cai, X., Wang, R. W., Yabut, J., Hartley, D. P., Evans, D. C. and Evers, R.: Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J. Pharmacol. Exp. Ther., 317: 579-589 (2006).
15. Conrad, S., Kauffmann, H. M., Ito, K., Deeley, R. G., Cole, S. P. and Schrenk, D.: Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet., 46: 656-663 (2001).
16. Fritz, F., Chen, J., Hayes, P. and Sirotnak, F. M.: Molecular cloning of the murine cMOAT ATPase. Biochim. Biophys. Acta., 1492: 531-536 (2000).
17. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S. and Kuwano, M.: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56: 4124-4129 (1996).
18. van Kuijck, M. A., van Aubel, R. A., Busch, A. E., Lang, F., Russel, F. G., Bindels, R. J., van Os, C. H. and Deen, P. M.: Molecular cloning and expression of a cyclic AMP-activated chloride conductance regulator: a novel ATP-binding cassette transporter. Proc. Natl. Acad. Sci. U S A, 93: 5401-5406 (1996).
19. Kauffmann, H. M., Keppler, D., Gant, T. W. and Schrenk, D.: Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch. Toxicol., 72: 763-768 (1998).
20. Ninomiya, M., Ito, K., Hiramatsu, R. and Horie, T.: Functional analysis of mouse and monkey multidrug resistance-associated protein 2 (Mrp2). Drug Metab. Dispos., 34: 2056-2063 (2006).
21. Ninomiya, M., Ito, K. and Horie, T.: Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab. Dispos., 33: 225-232 (2005).
22. Ishizuka, H., Konno, K., Shiina, T., Naganuma, H., Nishimura, K., Ito, K., Suzuki, H. and Sugiyama, Y.: Species differences in the transport activity for organic anions across the bile canalicular membrane. J. Pharmacol. Exp. Ther., 290: 1324-1330 (1999).
23. Hoffmann, K., Gastens, A. M., Volk, H. A. and Loscher, W.: Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res., 69: 1-14 (2006).
24. Potschka, H., Fedrowitz, M. and Loscher, W.: Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther., 306: 124-131 (2003).
25. van Vliet, E. A., Redeker, S., Aronica, E., Edelbroek, P. M. and Gorter, J. A.: Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia., 46: 1569-1580 (2005).
26. Aronica, E., Gorter, J. A., Ramkema, M., Redeker, S., Ozbas-Gerceker, F., van Vliet, E. A., Scheffer, G. L., Scheper, R. J., van der Valk, P., Baayen, J. C. and Troost, D.: Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia., 45: 441-451 (2004).
27. Baltes, S., Gastens, A. M., Fedrowitz, M., Potschka, H., Kaever, V. and Loscher, W.: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology, 52: 333-346 (2007).
28. Dombrowski, F., Stieger, B. and Beuers, U.: Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab. Invest., 86: 166-174 (2006).
29. Soontornmalai, A., Vlaming, M. L. and Fritschy, J. M.: Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience, 138: 159-169 (2006).
30. Tian, X., Zamek-Gliszczynski, M. J., Li, J., Bridges, A. S., Nezasa, K., Patel, N. J., Raub, T. J. and Brouwer, K. L.: Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice. Drug Metab. Dispos., 36: 61-64 (2008).
31. Takekuma, Y., Kakiuchi, H., Yamazaki, K., Miyauchi, S., Kikukawa, T., Kamo, N., Ganapathy, V. and Sugawara, M.: Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in humans is caused by different affinities of MRP2 to a glucuronized form. J. Pharm. Pharm. Sci., 10: 71-85 (2007).
32. Ito, K., Suzuki, H. and Sugiyama, Y.: Single amino acid substitution of rat MRP2 results in acquired transport activity for taurocholate. Am. J. Physiol. Gastrointest Liver Physiol., 281: G1034-1043 (2001).
33. Ito, K., Suzuki, H. and Sugiyama, Y.: Charged amino acids in the transmembrane domains are involved in the determination of the substrate specificity of rat Mrp2. Mol. Pharmacol., 59: 1077-1085 (2001).
34. Ryu, S., Kawabe, T., Nada, S. and Yamaguchi, A.: Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J. Biol. Chem., 275: 39617-39624 (2000).
35. Letourneau, I. J., Slot, A. J., Deeley, R. G. and Cole, S. P.: Mutational analysis of a highly conserved proline residue in MRP1, MRP2, and MRP3 reveals a partially conserved function. Drug Metab. Dispos., 35: 1372-1379 (2007).
36. Ito, K., Oleschuk, C. J.,Westlake, C., Vasa, M. Z., Deeley, R. G. and Cole, S. P.: Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem., 276: 38108-38114 (2001).
37. Zimmermann, C., van de Wetering, K., van de Steeg, E., Wagenaar, E., Vens, C. and Schinkel, A. H.: Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab. Dispos., 36: 631-640 (2008).
38. Borst, P., Zelcer, N., van de Wetering, K. and Poolman, B.: On the putative co-transport of drugs by multidrug resistance proteins. FEBS Lett., 580: 1085-1093 (2006).
39. Loe, D. W., Almquist, K. C., Deeley, R. G. and Cole, S. P.: Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J. Biol. Chem., 271: 9675-9682 (1996).
40. Van Aubel, R. A., Koenderink, J. B., Peters, J. G., Van Os, C. H. and Russel, F. G.: Mechanisms and interaction of vinblastine and reduced glutathione transport in membrane vesicles by the rabbit multidrug resistance protein Mrp2 expressed in insect cells. Mol. Pharmacol., 56: 714-719 (1999).
41. Bakos, E., Evers, R., Sinko, E., Varadi, A., Borst, P. and Sarkadi, B.: Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol., 57: 760-768 (2000).
42. Evers, R., de Haas, M., Sparidans, R., Beijnen, J.,Wielinga, P. R., Lankelma, J. and Borst, P.: Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br. J. Cancer, 83: 375-383 (2000).
43. Evers, R., Kool, M., van Deemter, L., Janssen, H., Calafat, J., Oomen, L. C., Paulusma, C. C., Oude Elferink, R. P., Baas, F., Schinkel, A. H. and Borst, P.: Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J. Clin. Invest., 101: 1310-1319 (1998).
44. Zelcer, N., Huisman, M. T., Reid, G., Wielinga, P., Breedveld, P., Kuil, A., Knipscheer, P., Schellens, J. H., Schinkel, A. H. and Borst, P.: Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J. Biol. Chem., 278: 23538-23544 (2003).
45. Bodo, A., Bakos, E., Szeri, F., Varadi, A. and Sarkadi, B.: Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem., 278: 23529-23537 (2003).
46. Chu, X. Y., Huskey, S. E., Braun, M. P., Sarkadi, B., Evans, D. C. and Evers, R.: Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J. Pharmacol. Exp. Ther., 309: 156-164 (2004).
47. Ito, K., Koresawa, T., Nakano, K. and Horie, T.: Mrp2 is involved in benzylpenicillin-induced choleresis. Am. J. Physiol. Gastrointest Liver Physiol., 287: G42-49 (2004).
48. Coppi, G., Monti, L. and Genova, R.: Choleretics and biliary excretion of antibiotics in rats. Chemotherapy, 16: 345-355 (1971).
49. Yang, B. and Hill, C. E.: Nifedipine modulation of biliary GSH and GSSG/ conjugate efflux in normal and regenerating rat liver. Am. J. Physiol. Gastrointest. Liver Physiol., 281: G85-94 (2001).
50. Guarino, A. M. and Schanker, L. S.: Biliary excretion of probenecid and its glucuronide. J. Pharmacol. Exp. Ther., 164: 387-395 (1968).
51. Takahashi, H., Sato, T., Shimoyama, Y., Shioda, N., Shimizu, T., Kubo, S., Tamura, N., Tainaka, H., Yasumori, T. and Echizen, H.: Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin. Pharmacol. Ther., 66: 569-581 (1999).
52. Walter-Sack, I., de Vries, J. X., Ittensohn, A., Kohlmeier, M. and Weber, E.: Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klin. Wochenschr., 66: 160-166 (1988).
53. Morikawa, A., Goto, Y., Suzuki, H., Hirohashi, T. and Sugiyama, Y.: Biliary excretion of 17beta-estradiol 17beta-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharm. Res., 17: 546-552 (2000).
54. Pal, A., Mehn, D., Molnar, E., Gedey, S., Meszaros, P., Nagy, T., Glavinas, H., Janaky, T., von Richter, O., Bathori, G., Szente, L. and Krajcsi, P.: Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2. J. Pharmacol. Exp. Ther., 321: 1085-1094 (2007).
55. Storch, C. H., Ehehalt, R., Haefeli, W. E. and Weiss, J.: Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J. Pharmacol. Exp. Ther., 323: 257-264 (2007).
56. Telbisz, A., Muller, M., Ozvegy-Laczka, C., Homolya, L., Szente, L., Varadi, A. and Sarkadi, B.: Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim. Biophys. Acta., 1768: 2698-2713 (2007).
57. Kimura, Y., Kioka, N., Kato, H., Matsuo, M. and Ueda, K.: Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem. J., 401: 597-605 (2007).
58. Kimura, Y., Kodan, A., Matsuo, M. and Ueda, K.: Cholesterol fill-in model: mechanism for substrate recognition by ABC proteins. J. Bioenerg. Biomembr., 39: 447-452 (2007).
59. Wang, E., Casciano, C. N., Clement, R. P. and Johnson, W. W.: Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem. Biophys. Res. Commun., 276: 909-916 (2000).
60. Maki, N. and Dey, S.: Biochemical and pharmacological properties of an allosteric modulator site of the human P-glycoprotein (ABCB1). Biochem. Pharmacol., 72: 145-155 (2006).
61. Amigo, L., Mendoza, H., Zanlungo, S., Miquel, J. F., Rigotti, A., Gonzalez, S. and Nervi, F.: Enrichment of canalicular membrane with cholesterol and sphingomyelin prevents bile salt-induced hepatic damage. J. Lipid Res., 40: 533-542 (1999).
62. Mazzone, A., Tietz, P., Jefferson, J., Pagano, R. and LaRusso, N. F.: Isolation and characterization of lipid microdomains from apical and basolateral plasma membranes of rat hepatocytes. Hepatology, 43: 287-296 (2006).
63. Cui, Y., Konig, J. and Keppler, D.: Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol. Pharmacol., 60: 934-943 (2001).
64. Sasaki, M., Suzuki, H., Ito, K., Abe, T. and Sugiyama, Y.: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem., 277: 6497-6503 (2002).
65. Huisman, M. T., Chhatta, A. A., van Tellingen, O., Beijnen, J. H. and Schinkel, A. H.: MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer, 116: 824-829 (2005).
66. Huisman, M. T., Smit, J. W., Crommentuyn, K. M., Zelcer, N., Wiltshire, H. R., Beijnen, J. H. and Schinkel, A. H.: Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids, 16: 2295-2301 (2002).
67. Lagas, J. S., van der Kruijssen, C. M., van de Wetering, K., Beijnen, J. H. and Schinkel, A. H.: Transport of diclofenac by BCRP (ABCG2) and stimulation of MRP2- (ABCC2-) mediated drug transport by diclofenac and benzbromarone. Drug Metab. Dispos., in press (2008).
68. Lou, H., Ookhtens, M., Stolz, A. and Kaplowitz, N.: Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells. Am. J. Physiol. Gastrointest. Liver Physiol., 285: G1335-1344 (2003).
69. Mano, Y., Usui, T. and Kamimura, H.: Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm. Drug Dispos., 28: 13-18 (2007).